MADISON, Wis.– Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation’s #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes common barriers of invasive screenings—like preparation and inconvenience—by allowing samples to be collected privately at home, with no special prep needed.
When caught early, colon cancer is survivable in about 90% of cases.3 Despite this, millions remain unscreened, including a higher proportion of African Americans, who face greater risks of diagnosis and death.4 The American Cancer Society recommends all adults 45+ at average risk get screened.5
Lil Jon is passionate about driving awareness of preventive health measures and screening options, like the Cologuard test. “Sometimes you gotta slow down and tune into your health,” said Lil Jon. “Some health topics can be uncomfortable to talk about, which can lead to people – especially Black men – not taking their health seriously until it’s too late. I re-worked one of my iconic records ‘Get Low’ to get people 45+ to ‘get low’ in a different way – this time, with an easier way to screen for colon cancer.”
Exact Sciences’ partnership with Lil Jon is part of ongoing efforts to reduce colon cancer diagnoses and deaths in the U.S. The collaboration features new content from Lil Jon remixing one of his top tracks to emphasize the importance of screening. Exact Sciences is also teaming up with the Atlanta Falcons to raise awareness within Atlanta communities.
“Colon cancer screening can be hard to prioritize for those 45+, so partnering with Lil Jon brings a fresh perspective that drives attention,” says Jeremy Truxal, VP of screening marketing at Exact Sciences. “We’re committed to making screening easier with the Cologuard test—a non-invasive, effective, and convenient option for those eligible.”
References
- Ebner DW, Kisiel JB, Fendrick AM, et al. Estimated Average-Risk Colorectal Cancer Screening-Eligible Population in the US. JAMA Netw Open. 2024;7(3): e245537.
- Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-254. doi:10.3322/caac.21772
- American Cancer Society. Colorectal Cancer Facts & Figures 2023–2025. Atlanta: American Cancer Society, Inc. 2022.
- Jackson CS, Oman M, Vega KJ. Health disparities in colorectal cancer among racial and ethnic minorities in the United States. J Gastrointest Oncol. 2016;(Suppl 1): S32-S43.
- American Cancer Society Guideline for Colorectal Cancer Screening. Accessed October 29, 2024.
